For the study, researchers examined samples of neonate fibrinogen and adult fibrinogen and compared their clot-forming processes. Researchers also combined the samples and examined the blood clot structures produced by the neonate-adult-fused blood.
Sign up for our FREE E-Weekly for more coverage like this sent to your inbox!
The study results found neonate fibrinogen formed more fragile clots that dissolved quicker than the adult samples. Researchers also found that the mixed samples formed weaker clots.
In a News Medical article, Nina Guzzetta, MD, corresponding author on the study, associate professor of anesthesiology at Emory University School of Medicine and a pediatric cardiac anesthesiologist at Children’s Healthcare of Atlanta, said, “This suggests that using adult fibrinogen in neonatal patients may pose an increased risk of embolism or other adverse thrombotic events.”
The findings suggest that alternative treatment strategies should be developed to reduce the morbidity of blood product transfusion in neonates.
More articles on quality:
The rise of urgent care: 5 findings and statistics
How can quality reporting be improved? 5 suggestions from physicians
Reporting quality measures is costly, not useful for physician practices, survey finds
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.